1. Introduction {#sec1}
===============

Chemotherapy is one of the common treatment options for cancer patients. It is conceivable that the efﬁcacy of a chemotherapy regimen relies on the maintenance of a drug at the effective dose and duration. Upon their administration, the chemotherapeutic agents need to go through the intracellular drug metabolism and disposition within the cancer cells and the liver, or other metabolic organs and tissues. Since most of the chemotherapeutic agents have a steep toxicity curve and a narrow therapeutic window, the intracellular drug retention is critical to ensure the therapeutic efficacy of these anti-neoplastic drugs. Decreased intracellular drug retention, usually caused by the dysregulation of enzymes and transporters responsible for the metabolism and disposition (uptake and efflux) of the anti-tumor agents, is one of the primary factors that limit effective cancer therapy[@bib1].

Drug metabolizing enzymes (DMEs) and transporters are crucial in the metabolism, elimination and detoxification of xenobiotics, including the clinical drugs. There are three major phases of drug metabolism and disposition: the phase I and phase II drug metabolism and the phase III drug disposition. Different tissues and organs in the human body are well-equipped with a variety of DMEs and transporters[@bib2]. The phase I enzymes are mostly cytochrome P450 (CYPs) that either activate or inactivate the drugs. The enzymes that fall into the category of phase II enzymes include uridine diphosphate glucuronosyltransferases (UGTs), sulfotransferases (SULTs), and glutathione *S*-transferases (GSTs). The key role of the phase II enzymes is to detoxify xenobiotics or mediate their bioactivation hence potentially toxic metabolites through a process called conjugation. In the phase III drug disposition, the parent drugs or their metabolites are eliminated and excreted by transporters[@bib3].

Recent studies have demonstrated that long noncoding RNAs (lncRNAs) are highly relevant to drug metabolism pathways and multidrug resistance in various types of cancers[@bib4]. LncRNAs represent a major type of noncoding RNAs. They are RNA transcripts larger than 200 nucleotides, but do not have protein-coding potentials[@bib5]. LncRNAs exert their biological functions as regulatory RNAs, serving as signals, guides, decoys, or scaffolds to regulate the expression of a wide range of target genes[@bib6], [@bib7], [@bib8]. Accumulating evidences suggest that dysregulation of lncRNAs is strongly associated with the development of chemo-resistance of various cancers[@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14]. Interestingly, it has been shown that the dysregulation of chemo-resistance-related lncRNAs can be effectively detected in body fluids of cancer patients[@bib15]^,^[@bib16], suggesting that lncRNAs can be used as diagnostic and prognostic biomarkers in patients[@bib9]. It is conceivable that functional studies of lncRNAs that are involved in drug metabolism and disposition will help to better understand and/or manage chemo-resistance in the clinic.

2. Regulation of drug metabolism and disposition by lncRNAs {#sec2}
===========================================================

2.1. Three phases of drug metabolism {#sec2.1}
------------------------------------

The phase I metabolism reaction may involve either of the following sequential, yet competitive chemical processes: oxidation, reduction, and hydrolysis[@bib17]. The human bodies are constantly exposed to a variety of chemicals, including agrochemicals, environmental pollutants and pharmaceutical products. These pharmacologically active substances are metabolized in the body, usually through the phase I metabolism catalyzed by the cytochrome P450 enzymes[@bib18]^,^[@bib19]. In addition to the pharmacologically activate substances (drugs), the pharmacologically inactive substances (prodrugs), after administration, are metabolized into active drugs by phase I enzymes, especially by the P450 enzymes[@bib20]^,^[@bib21]. The P450 enzymes alter the pharmacologic activities of many drugs and prodrugs and they also play an important role in their eliminations.

The phase II metabolic reactions can be considered chiefly as the detoxifying steps with some exceptions. The enzymes that fall under this category are broadly classified as transferases, including UDP-glucuronosyltransferases, sulfotransferases, *N*-acetyltransferases, glutathione *S*-transferases and methyltransferases[@bib22]. Besides playing a crucial role in the inactivation of pharmacologically active compounds, phase II reactions are involved in the biotransformation of endogenous compounds as well as xenobiotics to chemical forms that are more readily eliminated from the body due to increased water solubility upon conjugations[@bib23]. A compromised phase II metabolism may lead to increased toxicity of clinical drugs.

The phase III reactions mainly involve drug transporters that participate in the absorption, distribution, and elimination of drugs. Drug transporters include uptake and efflux transporters. Examples of the efflux transporters include the ATP-binding cassette (ABC) family such as the P-glycoprotein (P-gp) and multidrug resistance-associated proteins (MRPs)[@bib24]. The drug transporters are widely distributed in tissues and cells, determining the absorption and intracellular concentrations of drugs and hence directly affecting their pharmacokinetics. Increased expression and/or activity of efflux drug transporters represent a major mechanism for the development of cancer chemo-resistance. At present, the major members of the ABC transporters linked to multidrug resistance (MDR) in cancer cells include P-gp (ABCB1/MDR1), MRP1 (ABCC1), MRP2 (ABCC2), MRP4 (ABCC4) and BCRP (ABCG2). These transporters can efflux numerous structurally diverse, mainly hydrophobic compounds from cells, but each transporter has its preferred substrates. These transporters are the most widely studied in the context of drug response and toxicity. In some cancers, the dysregulation of these transporters is closely associated with poor overall prognosis and poor response to drug therapies[@bib25]^,^[@bib26].

2.2. Regulation of phase I enzymes by lncRNAs {#sec2.2}
---------------------------------------------

Quite a few studies have reported that lncRNAs are involved in the regulation of phase I drug metabolism by affecting the transcription of *CYP* genes. In one study, a transcriptional regulatory network containing nuclear receptors and lncRNAs that controls both the basal and drug inducible expression of CYPs was identified in the HepaRG cells[@bib27]. *HNF1α-AS1* and *HNF4α-AS1*, genes encoding two of the lncRNAs involved in this regulatory network, are located closely to the gene loci of hepatocyte nuclear factors 1*α* and 4*α* (HNF1*α* and HNF4*α*), two transcription factors essential for the regulation of CYP enzyme genes. A knockdown of *HNF1α-AS1* decreased the mRNA expression of *CYP*s, the nuclear receptors and *HNF4α-AS1*, but knockdown of *HNF4α-AS1* exhibited opposite regulatory effects on *CYP* gene expression. A subsequent study confirmed that knockdown or overexpression of *HNF1α-AS1* can significantly alter the expression of pregnane X receptor (PXR), a master regulator of DMEs including the CYPs, as well as the basal and rifampicin inducible mRNA expression of multiple CYPs, including CYP2B6, 2C8, 2C9, 2D6, 3C1 and 3A4[@bib28]. Notably, the regulation of CYP3 by *HNF1α-AS1* was independent of its sense coding gene *HNF1α*. HNF1*α* is a well-established nuclear receptor that regulates the transcription of CYPs and can induce the expression of *HNF1α-AS1*. However, *HNF1α-AS1* does not affect the expression of HNF1*α*. Further overexpression and knockdown experiments suggested that HNF1*α* can regulate the expression of aryl hydrocarbon receptor (AHR), another xenobiotic receptor that can regulate the expression of selected CYPs; whereas the effect of HNF1*α*-AS1 was more specific on PXR. The induction of CYP1A2, 2C8 and 2C19 by HNF1*α*-AS1 knockdown was also different from HNF1*α* knockdown. These results suggested that HNF1*α*-AS1 is involved in the regulation of P450s and their regulatory nuclear receptors in the human liver cells through a mechanism that is different from that of HNF1*α*.

Studies also identified other mechanisms concerning the regulatory role of lncRNAs on phase I metabolism. *Lnc-HC* has been reported to negatively regulate cholesterol metabolism in hepatocytes through its direct interaction with hnRNPA2B1^29^. Mechanistically, the *lnc-HC-hnRNPA2B1* complex binds to the mRNA of the mouse *Cyp7a1* or *Abca1* gene and decreases the protein translation of these two genes. Since CYP7A1 or ABCA1 are involved in the conversion of cholesterol to bile acids and cholesterol efflux, respectively, the down-regulation of CYP7A1 and ABCA1 resulted in reduced cellular cholesterol excretion. In contrast, knockdown of *lnc-HC* restored the cholesterol homeostasis in mice. Interestingly, the expression of *lnc*-*HC* itself can be regulated by high cholesterol exposure through the transcriptional factor CCAAT/enhancer-binding protein beta[@bib29]. In another example, *LncLSTR*, a liver-enriched lncRNA in mouse termed liver-specific triglyceride regulator, was found to down-regulate the expression of ApoC2 through an farnesoid X receptor (FXR)-mediated pathway, leading to the decrease of lipoprotein lipase activation and the inhibition of plasma triglyceride clearance. Mechanistically, *lncLSTR* and TDP-43 (a RNA and DNA binding protein) can form complexes that directly enhance the transcription of *Cyp8b1*, another key enzyme to convert cholesterol to bile acids, which engenders a bile pool and affects the ApoC2 expression through the bile acid receptor FXR[@bib30].

In addition to the CYP enzymes, lncRNAs have also been reported to regulate the expression of other phase I enzymes. Among examples, lncRNA *H19* can regulate the methylation of long interspersed nuclear elements-1 (LINE-1) through interacting with *S*-adenosylhomocysteine hydrolase (SAHH) in response to benzo\[*a*\]pyrene exposure[@bib31]. *H19* was also associated with the expression of aldehyde dehydrogenase 1 (ALDH1) in colorectal cancer stem cells[@bib32] and *H19* is highly expressed in ALDH1-positive breast cancer patients[@bib33]. Maternally expressed gene 3 (*MEG3*) is a lncRNA that has been reported to regulate the expression of alcohol dehydrogenases (ADHs). While *MEG3* is generally down-regulated in hepatocellular carcinoma, overexpression of *MEG3* can increase alcohol dehydrogenase 4 (ADH4) expression through competitive sponging of miR-664, which will further inhibit the proliferation of tumor cells, suggesting its role as a tumor suppressor[@bib34].

2.3. Regulation of phase II enzymes by lncRNAs {#sec2.3}
----------------------------------------------

Less is known about the regulation of phase II enzymes by lncRNAs. However, there have been reports suggesting that lncRNAs may contribute to the regulation of phase II enzymes. CHST15, a chondroitin sulfotransferase, is among the targets of HOX transcript antisense intergenic RNA (*HOTAIR*) and is required for *HOTAIR*-mediated invasiveness in breast cancer cell lines[@bib35]. Being closely correlated with the expression of CHST15 in primary and metastatic tumor lesions, overexpression of *HOTAIR* is necessary and sufficient for the transcription and downstream function of CHST15. The expression of *HNF1α-AS1* and *HNF4α-AS1* is also associated with the expression of sulfotransferases (SULTs) and UDP-glucuronosyltransferases (UGTs). In a study aiming to determine the impact of lncRNAs on acetaminophen (APAP)-induced hepatotoxicity, knockdown of these two lncRNAs significantly altered APAP-induced hepatotoxicity pathways, including APAP detoxification by UGTs and sulfation by SULTs, and detoxification through glutathione conjugation by glutathione-*S*-transferases (GSTs)[@bib36]. In the bacteria stain *Plutella xylostella* (L.), 64 lncRNAs were found to be differentially expressed between chlorantraniliprole-resistant and -sensitive strains. These lncRNAs exhibited a significant co-expression pattern with UGTs and P450 enzymes, suggesting their potential role in regulating UGTs and drug resistance[@bib37]. Another lncRNA that is found to be associated with the expression of phase II enzymes is lncRNA *NONMMUG032898.1*, which is an intronic lncRNA transcribed from the intron region of its neighboring protein coding gene *Ugt2b1*. *NONMMUG032898.1* and *Ugt2b1* were found to be up-regulated in the liver of male mice exposed to BDE-47, an environmental chemical that belongs to the polybrominated diphenyl ethers (PBDEs)[@bib38].

2.4. Regulation of drug transporters by lncRNAs {#sec2.4}
-----------------------------------------------

Many lncRNAs were identified as potential regulators for the drug transporters, including in the context of cancer chemotherapy. Among examples, lncRNA *MALAT1* can regulate the expression of the efflux transporters MRP1 and MDR1 *via* the activation of the transcriptional factor STAT3. The expression of *MALAT1* is elevated in cisplatin-resistant A549 lung cancer cells. *MALAT1* overexpression promotes the expression of MRP1 and MDR1, which in turn decreases cisplatin sensitivity both *in vitro* and *in vivo*. Niclosamide, a specific STAT3 inhibitor, can abolish the upregulation of MRP1 and MDR1 by MALAT1, suggesting that the regulation is STAT3-dependent[@bib39]. *ANRIL* is another lncRNA that is implicated in the regulation of MDR1 and MRP1. *ANRIL* is highly expressed in cisplatin-resistant cells and 5-FU-resistant gastric cancer tissues and cells. Knockdown of *ANRIL* decreased the cell proliferation and the expression of MDR1 and MRP1. A strong association between the expression of *ANRIL* and MDR1/MRP1 was also observed in gastric cancer tissues from patients. Further experiments demonstrated that knockdown of *ANRIL* reversed the cisplatin- and 5-FU-resistance in gastric cancer cells[@bib40]. *MRUL* is a lncRNA that up-regulates ABCB1 and induces multidrug resistance. The expression of *MRUL* is elevated in multidrug-resistant gastric cancer cell lines. Knockdown of *MRUL* in these cell lines led to increased apoptosis and reduced doxorubicin efflux. Moreover, *MRUL* depletion reduced *ABCB1* mRNA expression in a dose- and time-dependent manner, suggesting that ABCB1 is likely the regulatory target of *MRUL* to induce multidrug-resistance in gastric cancer[@bib41]. The lncRNA *Linc-VLDLR* is believed to be associated with the expression of ABCG2 and contributes to cell stress response. The expression of this lncRNA was significantly upregulated in the extracellular vesicles (EVs) derived from malignant human hepatocellular cancer tissues. Exposure of the hepatocytes to anti-neoplastic drugs, such as sorafenib, camptothecin and doxorubicin, increased the expression of *Linc-VLDLR* both inside the cells and in the EVs. *Linc-VLDLR* knockdown decreased the cell viability and reduced the expression of ABCG2, suggesting that *Linc-VLDLR* may be involved in cellular response to the anti-tumor drugs as an EV-enriched lncRNA[@bib42].

Additionally, there were several studies showing that lncRNAs can regulate the expression of drug transporters through microRNA sponging. For instance, lncRNA *XIST* was shown to positively regulate SGK1, which is a positive regulator of transporters, through direct sponging the SGK1-targeting microRNA miR-124, leading to doxorubicin resistance in colorectal cancer tissues and cell lines[@bib43]. LncRNA *KCNQ1OT1* has been reported to regulate oxaliplatin resistance through the miR-7-5p/ABCC1 pathway[@bib44]. *LINC00518* was found to be over-expressed in breast cancer tissues and chemo-resistant breast cancer cell lines. *LINC00518* can act as a molecular sponge of the MRP1 (ABCC1)-targeting miR-199a, leading to increased MRP1 expression and chemo-resistance. In contrast, knockdown of *LINC00518* enhanced the chemo-sensitivity to adriamycin, vincristine and paclitaxel[@bib45]. The lncRNA bladder cancer associated transcript-1 (*BLACAT1*) has also been shown to accelerate oxaliplatin-resistance of gastric cancer through promoting ABCB1 protein expression by sponging *miR-361*[@bib46].

Besides the ATP binding cassette family of transporters, lncRNAs are also reported to regulate the function of solute carrier family of transporters. For example, the trace element copper (Cu) is essential for life in numerous biological processes, the major copper importer in humans is the high-affinity copper transporter 1 (CTR1)[@bib47]^,^[@bib48]. In addition to copper, CTR1 has the ability to transport platinum-containing drugs[@bib49], [@bib50], [@bib51]. Recent studies reported that lncRNA nuclear enriched abundant transcript 1 (*NEAT1*) can regulate the CTR1 and could induce cisplatin sensitivity in non-small cell lung cancer (NSCLC) cells. Upregulation of *NEAT1* could competitively bind to *hsa-mir-98-5p*, which enhanced the green tea polyphenol (EGCG)-induced CTR1 expression and increased the drug accumulation in NSCLC cells[@bib52]. A further study from the same group showed that the expression of CTR1 was decreased, but the expression of *NEAT1* was increased in the enriched lung cancer stem cells. Knockdown or overexpression *NEAT1* decreased or increased the cancer stem cells (CSC) function in NSCLC/CSCs, which could modulate the chemo-resistance of NSCLC[@bib53].

3. Combining multi-omics data and machine learning to identify lncRNAs involved in chemo-resistance through drug metabolism and disposition {#sec3}
===========================================================================================================================================

By far, most of the lncRNA studies in drug metabolism have been using "bottom-up" strategies, which generate hypotheses based on documented lncRNA functions and then investigate the role of a particular lncRNA in a specific drug metabolism process. However, few studies were able to identify novel lncRNAs that have a direct relationship with drug metabolism. Since the majority of lncRNAs are poly-A tailed[@bib54], their expression information is buried within most of the RNA-seq data, which usually measures the abundance of poly-A tailed RNA molecules[@bib55]. Many of the existing RNA-seq analyses have focused on the protein-coding mRNAs. In this regard, repurposing the RNA-seq, DNA-seq and pharmacogenomic data, which have already been generated and deposited into public databases, can accelerate the discovery of novel lncRNAs that are master regulators of drug metabolism. We have summarized a list of publicly accessible datasets, including DNA-seq, RNA-seq and ChIP-seq data, that can be used to repurpose the lncRNA profiles for their potential effect on drug metabolism and drug resistance ([Table 1](#tbl1){ref-type="table"}). Recently, we integrated the pharmacogenomics data with lncRNA expression data in 5605 tumor samples and 505 cancer cell lines from 27 cancer types[@bib4]. We constructed lncRNA-based drug response prediction models and identified novel lncRNAs that are master regulators of cancer drug responses. Our analysis identified 27,341 lncRNA--drug interactions for 265 chemotherapy drugs. Moreover, the computational analyses have identified a group of "multi-drug resistant" lncRNAs, whose up-regulation is associated with resistance to more than 100 chemotherapy compounds, suggesting they may play important roles in drug metabolism and disposition. Indeed, our further pathway analysis indicated that the up-regulation of these "multi-drug resistant" lncRNAs is associated with the dysregulation of xenobiotic nuclear receptor target genes, including drug-metabolizing enzymes and transporters[@bib4].Table 1List of public-available genomic, transcriptomic or epigenetic studies on drug metabolism or drug resistance.Table 1StudiesPerturbationPhenotypeData typeSpeciesAccession IDTargeting palbociclib-resistant estrogen receptor-positive breast cancer cells *via* oncolytic virotherapyPalbociclibDrug resistanceRNA-seqHumanGSE130437Transcriptional changes in the breast cancer cell line MCF7 rendered resistant to the cationic drug siramesineSiramesineDrug resistanceRNA-seqHumanGSE130363Inhibition of the aryl hydrocarbon receptor/polyamine biosynthesis axis suppresses multiple myeloma and prostate cancer progressionAHR inhibitorDrug resistanceRNA-seqHumanGSE117160Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemiaVenetoclax/azacitidineMetabolism disruptionRNA-seqHumanGSE116567Patient adipose stem cell-derived adipocytes reveal genetic variation that predicts antidiabetic drug responseNot availableDrug responseRNA-seq/DNA-seqHumanGSE115421Transcriptome sequencing (RNA-Seq) of non-tumor kidney tissues from 36 patients undergoing nephrectomy for exploring the metabolic mechanism of sorafenib and identifying the major transcriptional regulation factors in sorafenib metabolism in kidneySorafenibDrug metabolismRNA-seqHumanGSE93069Quantitative profiling of the UGT transcriptome in human drug metabolizing tissuesNot availableNot availableRNA-seqHumanGSE82292The PGC-1*α*/ERR*α* axis represses one-carbon metabolism and promotes sensitivity to anti-folate therapy in breast cancerAMPK activationDrug sensitivityChIP-seqHumanGSE75877Genome-wide analysis of human constitutive androstane receptor (*CAR*) transcriptome in wild-type and *CAR*-knockout HepaRG cells*CAR* knockoutNot availableRNA-seqHumanGSE714468p Loss of heterozygosity triggers metastasis and drug resistance8p LOHMetastasis and drug resistanceRNA-seqHumanGSE68042Impact of CAR agonist ligand TCPOBOP on transcription factor binding in adult male mouse liverCAR agonistNot availableChIP-seqMouseGSE121915Dissecting the effect of genetic variation on the hepatic expression of drug disposition genes across the collaborative cross mouse strainsNot availableNot availableRNA-seqMouseGSE77715

The increasingly adopted Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-associated Protein 9 (CRISPR-Cas9) system can also provide tremendous data resources to study the regulation of drug metabolism and disposition by lncRNAs. CRISPR system has been successfully used in high throughput screening to discover lncRNAs that are associated with cancer drug resistance[@bib56]. A study in melanoma cells developed a genome-scale CRISPR-Cas9 gain-of-function activation system that targets more than 10,000 lncRNA transcriptional start sites. This study has identified 16 lncRNA loci whose induction can facilitate resistance to BRAF inhibitors by melanoma cells[@bib57]. Another study developed a CRISPR activation of lncRNA (CaLR) strategy to target 14,701 lncRNA genes in acute myeloid leukemia cell lines, in which 2874 lncRNAs were identified for their high therapeutic relevance to Ara-C drug resistance[@bib58]. Although the CRISPR screening for lncRNAs is still at its infant stage, these studies have reinforced the notion that lncRNAs can mediate cancer drug response. It is our believe that through integrating lncRNA profiling with drug metabolism pathway analysis will help to identify lncRNAs that affect drug resistance through their effect on drug metabolism and disposition.

Besides efforts that focused on genomic and epigenetic regulation of drug metabolism through lncRNAs, emerging metabolomic datasets may provide new direction for clarifying the landscape of drug metabolism in diseases. A recent study has profiled 225 metabolites related to cell growth, immune response, and xenobiotic metabolism in 928 cancer cell lines across 20 cancer types in the Cancer Cell Line Encyclopedia (CCLE)[@bib59]. With the paired genomic, transcriptomic, epigenetic and pharmacologic profiles available in the CCLE database, these datasets will enable unbiased association analysis to identify dependencies among cancer drug resistance, cell metabolism, and the lncRNA alterations.

In addition to lncRNAs that can directly regulate DMEs and transporters, some studies proposed that lncRNAs can also mediate the regulation of drug metabolism and disposition by xenobiotic receptors, such as PXR and CAR. For instance, a RNA-seq analysis on adult male C57BL/6 mouse livers treated with PXR and CAR agonists revealed that, among 3843 hepatic lncRNAs, 193 of them were differentially regulated by PXR or CAR[@bib60]. Genomic annotation found that most of these PXR- or CAR-responsive lncRNAs are produced from the introns and 3ʹ-UTRs of protein coding genes, and only a small fraction belong to intergenic lncRNAs. Further integration analysis with published PXR ChIP-seq data identified 774 lncRNAs with direct PXR-DNA binding sites, and 26.8% of them had significant changes in the binding after agonist exposure. Notably, most of these lncRNAs had positive enrichment of H3K4me2 and PXR near their gene loci, indicating a potential interaction between H3K4me2 and PXR to maintain the constitutive expression of liver-enriched lncRNAs. Knowing xenobiotic receptors are master regulators of drug metabolism and disposition, these results suggested a potentially important role of lncRNAs in mediating the PXR or CAR effect on xenobiotic metabolism. [Table 2](#tbl2){ref-type="table"} summarizes some of the publicly available transcriptome data that may help to facilitate the discovery of those lncRNAs that can directly participate in the drug metabolism.Table 2List of public-available transcriptomic studies on gene alterations after activation or ablation of xenobiotic nuclear receptors.Table 2StudiesSpeciesSample sizeMoleculesTreatmentGSE68365Mouse30 (5/group)CAR/PXRKnockoutGSE104734Mouse9 (3/group)CAR/PXRActivationGSE76148Human24 (6/group)CAR/PXR/PPARαActivationGSE71446Human12 (4/group)CARKnockoutGSE95685Mouse22 (3--4/group)CARActivation

4. Conclusions and perspectives {#sec4}
===============================

Drug metabolism and disposition represent a highly complex system that relies on an orchestrated regulation of DMEs and transporters at the cellular or organism levels. The regulations are relevant in both general drug metabolism, as well as drug metabolism and disposition in cancer chemotherapies. Since knowing the precise regulation of this process could help improve drug efficacy and reduce drug toxicity, great efforts have been made to improve the understanding of the mechanism of regulation. Previous studies have largely focused on the regulation of drug metabolism by regulatory proteins such as xenobiotic receptors, while recent and on-going studies have suggested a tremendous potential of lncRNAs in regulating the expression and/or activity of DMEs and transporters. Mechanistically and as summarized in [Fig. 1](#fig1){ref-type="fig"}, lncRNAs may have exerted their regulatory functions through their yet to be defined functional cross talk with the xenobiotic receptors, or through a post-transcriptional mechanism such as sponging the DME- and transporter-targeting miRNAs. Last but not least, lncRNAs may have participated in mediating the effectf of xenobiotic receptors on drug metabolism and disposition as xenobiotic receptor responsive genes. The studies on lncRNAs related to drug metabolism are still in their infancy; further understanding the role of lncRNAs in drug metabolism and disposition will help to identify novel regulatory mechanisms, enable the discovery of lncRNA-based biomarkers and drug targets, and personalize and improve the therapeutic outcome in patients, including the cancer patients.Figure 1Proposed model of regulation of drug metabolism and disposition through lncRNAs. lncRNAs may exert their regulatory functions through: 1) their yet to be defined functional cross-talk with the xenobiotic receptors; 2) a post-transcriptional mechanism such as sponging the DME- and transporter-targeting miRNAs; and 3) functioning as xenobiotic receptor responsive genes. XRE, xenobiotic response element.Figure 1
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